Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.
about
Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating diseaseTempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cellsCell death in the maintenance and abrogation of tolerance: the five Ws of dying cellsAntigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells.Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.Intrinsic and induced regulation of the age-associated onset of spontaneous experimental autoimmune encephalomyelitisTherapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune diseaseImmunotherapy of type 1 diabetes: where are we and where should we be going?γδ T cell subsets play opposing roles in regulating experimental autoimmune encephalomyelitis.Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor.'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptidesModulation of autoimmunity with artificial peptidesPrevention of "Humanized" diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approachChallenges in the pursuit of immune tolerance.T cells in the control of organ-specific autoimmunityInfusion of Sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate-Conjugated MOG35-55-Coupled Spleen Cells Effectively Prevents and Reverses Experimental Autoimmune Encephalomyelitis in MiceIntravenous tolerance effectively overcomes enhanced pro-inflammatory responses and experimental autoimmune encephalomyelitis severity in the absence of IL-12 receptor signaling.MOG(35-55) i.v suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways.The Peyer's patch is a critical immunoregulatory site for mucosal tolerance in experimental autoimmune encephalomylelitis (EAE)Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosisAntigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosisStem cell therapy for multiple sclerosis: preclinical evidence beyond all doubt?Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes.Taming the TCR: antigen-specific immunotherapeutic agents for autoimmune diseases.Immune response in pemphigus and beyond: progresses and emerging concepts.Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy.In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.Bystander immunotherapy as a strategy to control allergen-driven airway inflammation.T Cell Receptor Profiling in Type 1 Diabetes.Ethylenecarbodiimide-coupled allogeneic antigen presenting cells induce human CD4+ regulatory T cells.Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8+ T cell responses in type 1 diabetes.Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates.Gene Therapy for Autoimmune Disease.Apoptotic cell capture by DCs induces unexpectedly robust autologous CD4+T-cell responsesEarly IFNγ-Mediated and Late Perforin-Mediated Suppression of Pathogenic CD4 T Cell Responses Are Both Required for Inhibition of Demyelinating Disease by CNS-Specific Autoregulatory CD8 T Cells
P2860
Q24613288-5D6DCA6C-74BF-4D10-8CF1-AED08D45FD1CQ26851647-AC2675CE-2F24-47CD-9504-D74EED495C8BQ26999223-A846076F-9050-4CBB-AC11-1DF3D9BE8ECAQ27687250-F54101EB-4F89-4FE4-9183-B787E03647CFQ33687644-E0BE0CB4-E74C-4D86-BE2F-B70BB1DF7755Q33753720-27983C77-00C2-4FF6-8E7C-3C165C5213B5Q33784281-B88B6E15-4C1B-4E73-BA9D-B21763718584Q33785953-0D36D15C-6426-495D-8084-080CD8EA50B1Q33815506-32EC7187-5C4A-469B-9DC4-56C14CAE11B2Q33964713-AC22074D-BBC8-4CC9-9BD0-931832336CEDQ34070020-EA439C33-B2FE-4070-812F-E0955643F064Q34091080-63EEE2E7-FE4E-4810-BDEC-56592945FDF9Q34288089-206ECA9B-0CA5-4B47-83E3-5D74CA0C51B7Q34718795-658AF91B-6ADB-4889-8585-93D587CB3610Q34974448-EB1EC7CB-71CD-4B52-8284-D5DABCB3301CQ35836118-4F438954-7040-4F6B-9931-2AFF7EC187E1Q35894465-472974BB-BEC6-4475-8402-E9D4F06F1DC7Q35957480-B39CF06F-AE69-4FE5-A2BB-11F1BA56D284Q36366730-81401D7B-32A5-4CB4-AD15-B0FA36F6F06FQ36938320-C426677D-0AF7-42B3-B4C9-09225443B2A5Q37364480-2194A7F0-572B-45D5-8903-5991958191E2Q37679881-A8D1F05E-B53A-4829-88AA-D03E33D68EA7Q37991400-ADED54E2-99AD-4C05-BA9C-5F08CDBDF01CQ38117283-7568C14C-71B1-4CD4-9E5E-AD7D92580406Q38477340-2624919C-B063-47F2-AB7B-8EF0B266943BQ38644346-23423B18-DE89-468D-ADF8-E8B3DA2693A0Q38939073-D0216F13-2BA0-443B-863A-87B2A9BD6B56Q39245827-5F7C0BB7-D268-4C19-97B5-283C68E706E1Q42290134-921CD3A0-3946-457A-A9C8-D5A2EF345661Q42374922-8724EBEE-E25E-4469-86F2-8958345CDC86Q42589743-976391B4-7FB6-475E-95BF-72AD313D44FBQ48666099-9DB3A5D6-9224-454B-90BC-554DC813AC57Q50885724-EF99EB10-A005-483A-9CF1-9EF7189930E9Q53014578-B0D1A700-1A87-423A-9C14-EE13DE6F1078Q57583327-80CB30FD-F00A-45D5-BFAA-174A8F24F65DQ57816708-3A337046-CBFF-4BB1-BDE7-3978F9405754
P2860
Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Multi-peptide coupled-cell tol ...... e pathogenic autoreactivities.
@ast
Multi-peptide coupled-cell tol ...... e pathogenic autoreactivities.
@en
type
label
Multi-peptide coupled-cell tol ...... e pathogenic autoreactivities.
@ast
Multi-peptide coupled-cell tol ...... e pathogenic autoreactivities.
@en
prefLabel
Multi-peptide coupled-cell tol ...... e pathogenic autoreactivities.
@ast
Multi-peptide coupled-cell tol ...... e pathogenic autoreactivities.
@en
P2860
P1476
Multi-peptide coupled-cell tol ...... e pathogenic autoreactivities.
@en
P2093
Cassandra E Smith
Stephen D Miller
P2860
P304
P356
10.1016/J.JAUT.2006.12.002
P577
2006-12-01T00:00:00Z